Parkinson's Disease Psychosis: A Pharmacist's Update of New Treatment Options

Pharmacy Times, December 2016 Heart Health, Volume 82, Issue 12

This Continuing Education activity is supported by an educational grant from Acadia Pharmaceuticals Inc.

This activity is supported by an educational grant from Acadia Pharmaceuticals Inc.

Parkinson's Disease Psychosis: A Pharmacist's Update of New Treatment Options

Faculty

Jack J. Chen, PharmD, BCPS, BCGP, FASCP, FCCP

Department of Pharmacy Practice College of Pharmacy

Marshall B. Ketchum University Fullerton, California

Movement Disorders Center Department of Neurology Loma Linda, California

Educational Objectives

After completing this continuing education program, the participant will be able to:

  • Identify the clinical features and risk factors of Parkinson’s disease psychosis (PDP)
  • Differentiate the pharmacology, safety, and efficacy of available pharmacologic treatment options for PDP
  • Explore optimal management strategies for patients with PDP

Target audience: Pharmacists

Type of activity: Application

Release date: December 12, 2016

Expiration date: December 12, 2017

Estimated time to complete activity: 2.0 hours

Fee: Free

Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-16-152-H01-P. The activity is available for CE credit through December 12, 2017.